Key financial details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Net Loss | Miss | $36.80 mln | $22.79 mln (5 Analysts) |
| Q2 Operating Income | Miss | -$27 mln | -$22.07 mln (5 Analysts) |
| Q2 Loss Per Basic Share | | $0.16 | |
| Q2 Operating Expenses | | $27.40 mln | |
Outlook and clinical plans
- Humacyte plans to file an sBLA for ATEV dialysis access with the FDA in H2 2026
- Company expects to start Phase 2a CTEV CABG study in Q3 2026
- Humacyte reports strengthening Symvess adoption and utilization in influential hospitals in H2 2026
- Company plans sBLA filing for dialysis access after breakthrough Phase 3 results for ATEV
Quarterly results and key drivers
HUMA•
